Micro Interventional Devices Raises $250K
2012-03-05
BETHLEHEM, PA, The Life Sciences Greenhouse of Central Pennsylvania announced an investment of $250,000 in Micro Interventional Devices, a developer of structural heart repair technologies.
The Life Sciences Greenhouse of Central Pennsylvania (www.LSGPA.com) announced an investment of $250,000 in Micro Interventional Devices, Inc. (MID), a developer of structural heart repair technologies.
"It is our hope that Permaseal becomes the new standard of care for access and closure for these procedures."
MID's initial product offering is a minimally invasive device known as Permaseal, which provides access and wound closure during structural heart repair procedures. Designed to move with the beating heart while still keeping the edges of the wound closed, the Permaseal device not only enables wound healing without the use of sutures, it is cost- and time-efficient.
"The Permaseal access and closure device will enable unprecedented safe and reliable transmyocardial access for structural heart repair procedures," says Michael Whitman, President & CEO. "It is our hope that Permaseal becomes the new standard of care for access and closure for these procedures."
The patent pending Permaseal technology allows the surgeon to remotely affix a biocompatible implant to the apex of the heart, creating an "access site" on the myocardial surface of the heart. This provides sutureless access for a wide range of structural heart repair procedures including transcatheter aortic valve implantation (TAVI), transcatheter mitral valve replacement, mitral valve repair and other emerging structural heart repair procedures.
Micro Interventional Devices, Inc. (MID) is an early stage cardiovascular medical device company founded in May of 2010. MID is developing solutions to unmet needs in structural heart repair procedures, including transcatheter aortic valve implantation (TAVI), transcatheter mitral valve replacement, LVAD placement, mitral valve repair, valvuloplasty, aortic arch repair, ASD and VSD closure, left atrial appendage closure, ablation of arrhythmia and other emerging structural heart repair procedures. Located in Bethlehem, PA, MID is developing proprietary technology based on a breakthrough in soft-tissue anchoring and associated delivery devices that enable off-pump procedures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors